SINGAPORE—On April 14, Alcon officially opened its new $200 million, 330,000-square-foot pharmaceutical manufacturing facility in the Tuas Biomedical Park. Located here to be closer to Alcon’s growing base of customers in Asia, the plant produces ophthalmic pharmaceutical products which address eye conditions such as glaucoma, dry eye, allergies and bacterial infections.

Alcon’s top five products produced at the facility are Systane, Travatan, Patanol, Tobradex and Vigamox, a company spokesperson told VMail. Currently, the facility employs approximately 150 associates, and is expected to continue to grow as production increases. Alcon already operates another manufacturing facility in Tuas Biomedical Park, which opened in 2005 to produce Dailies contact lenses.

“The need for quality eyecare is increasing rapidly across Asia, as the population grows and ages,” said Roy Acosta, area president, Alcon Asia-Pacific. “With the opening of this new manufacturing facility, Alcon is making a strong investment in the future of our business in Asia, and ensuring that our innovative products are readily available to those who need them.”